NCT07004686 Effect of MGRNOX-Guided General Anesthesia on Opioid Consumption in Patients
| NCT ID | NCT07004686 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking University Shenzhen Hospital |
| Condition | Opioid Use |
| Study Type | INTERVENTIONAL |
| Enrollment | 112 participants |
| Start Date | 2025-06-28 |
| Primary Completion | 2026-05-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 112 participants in total. It began in 2025-06-28 with a primary completion date of 2026-05-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
1. Pain management is a crucial part of general anesthesia surgery. Nociception monitoring can help anesthesiologists better titrate the use of intraoperative analgesic drugs, especially the opioid. 2. Although a variety of nociception monitoring devices have been developed to date, there is not a specific monitoring indicator that serves as the "gold standard" to objectively guide analgesic management in general anesthesia. 3. The MGRNOX index, which is derived from electroencephalogram (EEG), is used to reflect the correlation between noxious stimuli and opioid analgesics in a state of general anesthesia by converting and quantifying the EEG signals collected by the instrument. However, no studies have so far verified the effect of the MGRNOX index-guided analgesic management of general anesthesia on the consumption of opioids in patients. 4. This study aims to explore the effect of MGRNOX index-guided general anesthesia on opioid consumption in patients undergoing laparoscopic cholecystectomy and the primary hypothesis of our study is that using the MGRNOX index to guide intraoperative pain management during general anesthesia can significantly reduce the consumption of remifentanil during the surgery.
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years old and \< 65 years old； * American Society of Anesthesiologists (ASA) class I-II； * Scheduled to undergo elective laparoscopic cholecystectomy undergeneral anesthesia （without epidural anesthesia, local blocks, or infiltration） Exclusion Criteria: * Pregnancy or lactation period； * BMI ≥35 kg/m² or \<18.5 kg/m²； * Anticipated difficult airway； * Previous diagnosis of hypertension； * History of drug or alcohol abuse within the past 6 months； * Preoperative acute or chronic pain history (routine preoperative use of opioid or non-opioid analgesics), peripheral or central nervous system-related disorders； * Definitively diagnosed psychiatric disorders or other neuropsychiatric conditions severely affecting cognitive judgment, history of psychotropic medication use； * Allergy or intolerance to anesthetic agents； * Baseline mean arterial pressure (MAP) \<60 mmHg or \>120 mmHg; baseline heart rate (HR) \<45 bpm or \>90 bpm (Baseline values defined as first measurement taken in the ward after admission)； * History of severe underlying diseases (untreated or ongoing peripheral/central cardiovascular diseases, severe hepatic disorders with elevated bilirubin/INR or hypoalbuminemia, severe renal diseases with elevated creatinine, severe pulmonary diseases potentially causing acute respiratory failure or persistent dyspnea)； * Implanted pacemaker, chronic arrhythmia, preoperative use of prescribed anticholinergics, α2-adrenergic agonists, beta-1 adrenergic antagonists, or antiarrhythmic medications.
Contact & Investigator
Tao Luo, MD,PHD
PRINCIPAL INVESTIGATOR
Peking University Shenzhen Hospital
Frequently Asked Questions
Who can join the NCT07004686 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 64 Years, studying Opioid Use. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07004686 currently recruiting?
Yes, NCT07004686 is actively recruiting participants. Contact the research team at luotao_wh@yahoo.com for enrollment information.
Where is the NCT07004686 trial being conducted?
This trial is being conducted at Shenzhen, China.
Who is sponsoring the NCT07004686 clinical trial?
NCT07004686 is sponsored by Peking University Shenzhen Hospital. The principal investigator is Tao Luo, MD,PHD at Peking University Shenzhen Hospital. The trial plans to enroll 112 participants.